Literature DB >> 1939652

Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs.

J P Allain1, S H Dailey, Y Laurian, D S Vallari, A Rafowicz, S M Desai, S G Devare.   

Abstract

Hepatitis C virus (HCV) is the major etiologic agent associated with non-A, non-B hepatitis. This study was designed to assess virologic and serologic markers in hemophiliacs exposed to non-heat-treated and/or virus-inactivated plasma derivatives. Serial bleeds from 48 hemophilic patients were analyzed for the presence of HCV viral RNA sequences as detected by polymerase chain reaction (PCR) and antibodies to structural (core) and nonstructural (C-100 and 33C) proteins by specific dot immunoblot assay. All patients exposed to non-heat-treated products, and four of six patients exposed only to virus inactivated products, had evidence of HCV infection. However, over the 5-yr study period, six exposed patients (13%) consistently lacked detectable anti-C-100 and seven (15%) lost this antibody. HCV viremia (PCR positive) was found in 91% of exposed patients, and was significantly more frequent in HIV seropositive hemophiliacs (P less than 0.05). Six patients had high antibody level to HCV and elevated ALT, but appeared to clear viremia. Four hemophiliacs were HCV seropositive but lacked detectable viremia. These data indicate that hemophiliacs remain persistently infected by HCV and that antibody to the core antigen of HCV is a reliable marker of this transfusion transmissible agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939652      PMCID: PMC295699          DOI: 10.1172/JCI115482

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Hepatitis C virus RNA in saliva of patients with post-transfusion hepatitis C infection.

Authors:  J T Wang; T H Wang; J T Lin; J C Sheu; S M Lin; D S Chen
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

2.  Antibodies to hepatitis C virus in haemophilia.

Authors: 
Journal:  Lancet       Date:  1989-09-02       Impact factor: 79.321

3.  Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen.

Authors:  M E Lai; P Farci; A Figus; A Balestrieri; M Arnone; G N Vyas
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

4.  Enzyme immunoassay system for panel testing.

Authors:  J Donohue; M Bailey; R Gray; J Holen; T M Huang; J Keevan; C Mattimiro; C Putterman; A Stalder; J Defreese
Journal:  Clin Chem       Date:  1989-09       Impact factor: 8.327

5.  Non-A, non-B hepatitis and heat-treated factor VIII concentrates.

Authors:  F E Preston; C R Hay; M S Dewar; M Greaves; D R Triger
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.

Authors:  K Schimpf; P M Mannucci; W Kreutz; H H Brackmann; G Auerswald; N Ciavarella; J Mösseler; V DeRosa; B Kraus; C Brueckmann
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.

Authors:  M Colombo; P M Mannucci; V Carnelli; G F Savidge; C Gazengel; K Schimpf
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

9.  Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.

Authors:  M S Horowitz; C Rooks; B Horowitz; M W Hilgartner
Journal:  Lancet       Date:  1988-07-23       Impact factor: 79.321

10.  Occurrence of normal circulating proalbumin in a hemophilic A patient after acute hepatitis related to the delta virus.

Authors:  J M Fine; J P Allain; D Rochu; M Marneux
Journal:  Clin Chem       Date:  1986-10       Impact factor: 8.327

View more
  4 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates.

Authors:  J Woelfle; T Berg; R Bialek; K M Keller; W Effenberger; N Wagner
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

3.  Identification of GB virus C variants by phylogenetic analysis of 5'-untranslated and coding region sequences.

Authors:  A S Muerhoff; D B Smith; T P Leary; J C Erker; S M Desai; I K Mushahwar
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C.

Authors:  M E Eyster; J C Sanders; M Battegay; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.